Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: nonselective beta blocker, cardio-selective beta blocker group, alendronate sodium.
- Who it may be relevant to
- Registry conditions: Beta Blocker Toxicity. Basic parameters: from 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Study Evaluating Selective or Nonselective Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
Overview
Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis
Detailed description
Clinical study evaluating selective or nonselective beta blockers use and if there is fracture risk in patients with primary osteoporosis
Interventions
- Drug nonselective beta blocker
nonselective beta blocker - Drug cardio-selective beta blocker group
cardio-selective beta blocker group - Drug alendronate sodium
alendronate sodium
Primary outcome measures
- Number of patients with fracture in each group [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
- • Male \& female osteoporotic patient aged ≥ 50 years
- Hypertensive \& normotensive patients
- BMD T-score ≥ 2.5 or more SD below peak bone mass
Exclusion criteria
- Patients on drugs that may improve osteoporosis disease state such as:
- Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.
Patients on drugs that may worsen osteoporosis disease state such as:
- Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Sherief Abd-Elsalam — Tanta
Identifiers
NCT: NCT04704947 · osteoprosis